Investing in Israeli Femtech


Sharon Handelman-Gotlib
Sompo Digital Lab, FemTech IL

FemTech is a broad field, encompassing everything from heart disease to reproductive treatment, from oncology to menopause, and from breast feeding to menstrual cycles. We learn that the two genders require different treatment regimens and demonstrate different symptoms for the onset of various diseases.

This podcast discusses issues such as:

  • How should medical devices be designed to best suit women practitioners?
  • To what extent do women’s health therapies need to be modified according to the patient’s ethnicity?
  • What are the pros and cons of diagnosing women via telemedicine?
  • To what extent is technology from Israel’s military utilized in furthering femtech?
  • What aspects of menopause are targeted for treatment?
  • What advances are being made in enhancing fertility and in detecting complications with fetuses?

Sharon Handelman-Gotlib, Business Development Manager, Sompo Digital Lab

Sharon Handelman-Gotlib is the Business Development Manager at the Sompo Digital Lab in Tel Aviv. Sharon is a member of the FemTech IL management team.

 

TOPIC:

Accounting/Valuation

INDUSTRY:

FemTech

AFFILIATION:

Sompo Digital Lab, FemTech IL

SUBSCRIBE

iTunes | Spotify | Google Podcasts | Amazon Music | Tune In | Listen Notes | Pocket Casts | Pod Chaser | Deezer | Stitcher

SHOW NOTES:

00:00:59 – And Stumpo is a very large Japanese insurance company…

I’ve been working in pharma and health and innovation in the last I’d say decade or so started with pharmaceutical Teva, working in Teva and then continuing to lead the innovation at Maccabi, which is the second largest HMO in Israel.

And working into those areas is the focus of finding the right technologies, the right solutions mainly on the digital high space to support patients, consumers, customers. And of the essence of it all, supporting our health and well-being So today in parts of Sumpa in the innovation channel or network as part of the largest sample corporate which is an insurance company at the essence of it. And Stumpo is a very large Japanese insurance company.

However, it works and has footprint in over 30 countries around the globe and mainly focusing on life insurance and property and cash casualty, which is the core kind of products that they bring to the table.

00:09:48 – And the question is fair, what is femtech?

And I’ve kind of we’ve established this community and I’ve been part of that in the last year and a half and we’ve grown, we have in our community almost 4000 people being part, some are more active, some are even more active active in the community. But the idea is.

To kind of promote the discussion, awareness and collaboration between our community members in the ecosystem, in the Israeli ecosystem.

And the question is fair, what is femtech?

And I’d say that’s a good question because for many, a many have different answers to that. I tried to simplify the answer into a very basic one, which is the, I’d say more.

00:28:23 – What do I mean by mostly physicians, male physicians, and tried out on mail?

So please cut me when they’re coming charming time and tell me when to stop. And I’ll say that is one of the key areas of challenges.

And I think the i’d say the evils of why we need femtech and why is so important for us to have the discussion.

So historically, for many reasons, clinical trials, medicine development and medical treatments devices were created. Buy and four for men.

What do I mean by mostly physicians, male physicians, and tried out on mail? On male population, so if you’re looking to example the example, the you shared the heart attacks and all the cardiology area.

Those were clinical trials, white what were conducted on a very specific profile of a person, typically an average white male, the age of 45 and therefore all the conditions are fairly.

00:34:47 – And this is part of a huge movement and it also great expert.

You’re correct, we will have women will have a different set of symptoms. So it’s not necessarily holding kind of her chest and saying I have pain. No, totally.

Different symptoms therefore because the historically the set of criterias were defined by men, for men this would be ignored and not considered as an issue or a symptom of an index or indication of something going on and what we’re doing now and changing that.

And this is part of a huge movement and it also great expert.

I can give examples of great work by Doctor Avital Paltel in the Bailey.

00:40:16 – I’ll give you an example, a very close one historically when Pfizer conducted.

Well, today I’d assumed they’d be closer to equal if not equal then much closer in the past because in the past it was absolutely nothing or very close to that and again for numerous reasons.

And as I said, it’s shifting, but it takes time. I’ll give you an example, a very close one historically when Pfizer conducted.

When the conducted clinical studies were conducted

00:48:46 – When you go through a medication and pharmaceutical approval process you have before going into human studies and research.

So it can be, if you can, you can then claim that it’s always a valid or argument for any kind of cardiology and claims or any other type of disease which is I’d say equal.

And therefore, again, when you go through far, when you go through a medication and pharmaceutical approval process you have before going into human studies and research, you have stages.

Before that. To consider and to support the efficacy and to reduce the risk. I’m no pharma expert even though I worked in pharma to explain that and they can go into that as well in details.

OTHER RESOURCES:

1) Enhanced Negotiating Strategies: This two-day seminar discusses the most intense negotiating strategies and tactics allowed without violating your ethics or morals

2) Valuation of Emerging Technologies: This seminar provides an in-depth review of more than 20 Valuation Methodologies

3) Solution Nation – The Book: Learn how the world’s most disadvantaged and destitute people stand to benefit from Israeli ingenuity.